Drug Profile

Ondansetron companion diagnostic - ADial Pharmaceuticals

Latest Information Update: 20 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

11 Feb 2025 ADial Pharmaceuticals has patent protection for a proprietary genetic diagnostic panel, in combination with ondansetron for the treatment of alcohol use disorder and opioid use disorder in the US
13 Aug 2024 Adial Pharmaceuticals and Boudicca Dx agree to co-develop Ondansetron companion diagnostic for Alcoholism
13 Aug 2024 Adial Pharmaceuticals plans a phase III trial for Alcoholism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com